The combination of amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, with the third-generation tyrosine kinase inhibitor lazertinib is used to overcome drug resistance in the treatment of non-small cell lung carcinoma (NSCLC). We present a 58-year-old woman with NSCLC who developed tarsoconjunctival granulation tissue while she was under amivantamab-lazertinib combination therapy. After the excision of tarsoconjunctival granulation tissue, she was maintained on amivantamab-lazertinib combination therapy. Tarsoconjunctival lesions recurred and she also developed trichomegaly and paronychia, which are well-known side effects of EGFR inhibitors. This case presentation aims to raise awareness among ophthalmologists and oncologists of the association between EGFR-Is and an unusual side effect; tarsoconjunctival granulation tissue formation.